Format

Send to

Choose Destination
J Cyst Fibros. 2019 Sep;18(5):677-684. doi: 10.1016/j.jcf.2019.06.011. Epub 2019 Jul 11.

Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery.

Author information

1
National Heart & Lung Institute, Imperial College London, UK; Royal Brompton & Harefield NHS Foundation Trust, London, UK. Electronic address: j.c.davies@imperial.ac.uk.
2
Motol University Hospital Prague, Czech Republic.
3
Queens University, Belfast, UK.
4
Hadassah Hebrew University Medical Center, Jerusalem, Israel.
5
Leeds Teaching Hospitals NHS Trust, Leeds, UK.
6
University of Lisboa, Portugal.
7
University of Leuven, Belgium.
8
National Heart & Lung Institute, Imperial College London, UK; Royal Brompton & Harefield NHS Foundation Trust, London, UK.

Abstract

The last decade has witnessed developments in the CF drug pipeline which are both exciting and unprecedented, bringing with them previously unconsidered challenges. The Task Force group was brought together to consider these challenges and possible strategies to address them. Over the last 18 months, we have discussed internally and gathered views from a broad range of individuals representing patient organisations, clinical and research teams, the pharmaceutical industry and regulatory agencies. In this and the accompanying article, we discuss two main areas of focus: i) optimising trial design and delivery for speed and efficiency; ii) drug development for patients with rare CFTR mutations. We propose some strategies to tackle the challenges ahead and highlight areas where further thought is needed. We see this as the start of a process rather than the end and hope herewith to engage the wider community in seeking solutions to improved treatments for all patients with CF.

KEYWORDS:

CFTR modulators; Clinical trial design; Cystic fibrosis

PMID:
31303382
DOI:
10.1016/j.jcf.2019.06.011

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center